Skip to main content
US EQUITIES PRE-MARKET CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
GI

GILDStock

Nasdaq Global Select Market · Healthcare · US

$166.53 last close 2026-11-19
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment GILD's does — no target price to set, unlike a price alert.

Stable Ratio screen, 4 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
COMPLIANT
Per our in-house ratio engine
4 of 7 pass our own screen — the standards disagree
🕌 Held by HLAL · MNZL Purification 1.17% *HTR non-permissible income 1.19%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
🟢 STRONG BUY SETUP
Strong confluence across multiple layers — outperforming the market by 12.2%, RSI in healthy zone, Wall Street...
Scores: 4 bullish / 1 bearish
34
of 100
Setup confidence — system conviction, not win probabilityF

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

ORB · SCALP
Entry
$160.29
Stop
$158.36
Target
$164.14
Risk : Reward 2.0R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 17.4% aligned
VWAPPrice below VWAP ($168.62)
VolumeRelative volume 2.7× the 20-day average
Momentum10-day rate of change -0.6%
Overall readSTRONG BUY SETUP

GILD is currently considered halal (Sharia-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
BUY
37 analysts
Institutional own.
92.3%
of shares
Momentum (10d)
-0.6%
rate of change
SMC grade
F · 34
17.4% aligned
🕌 HLAL, MNZL
Held by real halal ETF(s)
1.17% *
Purification ratio (secondary provider, uncertain)
1.19%
Non-permissible income — HTR, from filings (2026-09-30)
F · 34
SMC grade — 17.4% timeframe alignment
-0.6%
Rate of change (10d)
BUY
Wall Street consensus (37)
92.3%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to GILD’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 19, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $207.9B as of 2026-11-17. At the 2026-11-19 close it is about $206.6B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 12.7% (12.6% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 3.1% (3.1% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 12.62% 30.00% Pass(17.4pp buffer)
Interest-bearing investments 3.10% 30.00% Pass(26.9pp buffer)
Non-permissible income 1.19% 5.00% Pass(3.8pp buffer)
Usmani Fail 4 of 5 ratios pass
RatioValueThresholdResult
Interest-bearing debt 51.03% 33.00% Fail(18.0pp over)
Interest-bearing investments 12.52% 33.00% Pass(20.5pp buffer)
Non-liquid assets 77.74% at least 20.00% Pass(57.7pp above the floor)
Non-permissible income 1.19% 5.00% Pass(3.8pp buffer)
Net liquid assets per share $-558.0M under mkt cap $207.9B Pass
MSCI Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 51.03% 33.33% Fail(17.7pp over)
Cash + interest-bearing securities 12.52% 33.33% Pass(20.8pp buffer)
Accounts receivable 22.26% 33.33% Pass(11.1pp buffer)
Non-permissible income 1.19% 5.00% Pass(3.8pp buffer)
FTSE Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 51.03% 33.33% Fail(17.7pp over)
Cash + interest-bearing securities 12.52% 33.33% Pass(20.8pp buffer)
Accounts receivable 22.26% 50.00% Pass(27.7pp buffer)
Non-permissible income 1.19% 5.00% Pass(3.8pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 17.38% 33.00% Pass(15.6pp buffer)
Cash + interest-bearing securities 4.26% 33.00% Pass(28.7pp buffer)
Accounts receivable 3.32% 33.00% Pass(29.7pp buffer)
Non-permissible income 1.19% 5.00% Pass(3.8pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 20.16% 33.00% Pass(12.8pp buffer)
Cash + interest-bearing securities 4.95% 49.00% Pass(44.1pp buffer)
Accounts receivable 3.85% 49.00% Pass(45.2pp buffer)
Non-permissible income 1.19% 5.00% Pass(3.8pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 20.16% 33.33% Pass(13.2pp buffer)
Cash + interest-bearing securities 4.95% 33.33% Pass(28.4pp buffer)
Accounts receivable 8.79% 49.00% Pass(40.2pp buffer)
Non-permissible income 1.19% 5.00% Pass(3.8pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 3.8pts
Usmani (% of total assets)non permissible income ratio 3.8pts
Dow Jones Islamic Market (% of 24-mo avg market cap)non permissible income ratio 3.8pts
Usmani (% of total assets)debt ratio 18.0pts
MSCI Islamic Index (% of total assets)debt ratio 17.7pts
FTSE Shariah Global Equity Index Series (% of total assets)debt ratio 17.7pts

The numbers the ratios are built from

Read from GILD's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $29.4B 2026-09-30 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtShort and long-term borrowings $26.2B 2026-09-30 LongTermDebtNoncurrent, LongTermDebtCurrent
Cash and interest-bearing securitiesCash, equivalents and marketable securities $6.4B 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, MarketableSecuritiesCurrent
Total assetsBalance sheet total $51.4B 2026-09-30 Assets
Market capDenominator for AAOIFI $207.9B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $128.7B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $149.3B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $349.0M 2026-09-30 10-K text (no XBRL tag available)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-10-30, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-02-24, period ended 2026-09-30. Screened 2026-11-17.

  • Total assets$51.4B
    Assets · period ended 2026-09-30 · 10-Q filed 2026-10-30
  • Interest-bearing debt$26.2B
    LongTermDebtNoncurrent $23.8B · period ended 2026-09-30 · 10-Q filed 2026-10-30
    LongTermDebtCurrent $2.4B · period ended 2026-09-30 · 10-Q filed 2026-10-30
  • Cash and interest-bearing securities$6.4B
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents $6.4B · period ended 2026-09-30 · 10-Q filed 2026-10-30
    MarketableSecuritiesCurrent $0 · period ended 2026-09-30 · 10-Q filed 2026-10-30
  • Receivables$5.0B
    AccountsReceivableNetCurrent · period ended 2026-09-30 · 10-Q filed 2026-10-30
  • Revenue$29.4B
    RevenueFromContractWithCustomerExcludingAssessedTax · period ended 2025-12-31 · 10-K filed 2026-02-24
  • Interest income (non-permissible)$349.0M
    10-K text (no XBRL tag available) · income statement as of 2026-09-30 · no filing link for this figure
  • Market cap$207.9B
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-17 · not a filing figure, so no link

7 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for GILD. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for GILD has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Revenue by business segment

Not disclosed by segment: the latest 10-K (fiscal year ended 2025-12-31) does not tag its revenue by product, service or business segment in its XBRL, so there is no split to show. None is estimated.

Source: 10-K filed 2026-02-24 (accession 0000882095-26-000006), read from its XBRL on SEC EDGAR.

What would change the status

The headline verdict is the majority of the decided ratio standards — 4 pass and 3 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-17.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio (12.6% against a 30% line) would only fail if the market cap fell by 58%, to $87.4B. At the 2026-11-19 close it would read 12.7%.

AAOIFI's investments ratio (3.1% against a 30% line) would only fail if the market cap fell by 90%, to $21.5B. At the 2026-11-19 close it would read 3.1%.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Drug Manufacturers - General listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
LLYLilly(Eli) & Co $1.2T —
JNJJohnson & Johnson $658.0B $267.14-2.04%
ABBVAbbvie Inc $467.4B —
MRKMerck & Co Inc $371.7B —
NVSNovartis AG - ADR $306.5B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold GILD

40 of the 279 funds whose filed holdings we currently hold own GILD shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns GILD.

Shariah funds
FundGILD in fundFund compliant by weight
MNZL Manzil Russell Halal USA Broad Market ETF 0.56% 88%
SPUS SP Funds S&P 500 Sharia Industry Exclusions ETF 0.47% 79%
HLAL Wahed FTSE USA Shariah ETF 0.46% 72%
You may already own it

Widely held U.S. index funds. If you own one, you own GILD through it. None of them is a Shariah fund; the last column is our look-through of each.

FundGILD in fundFund compliant by weight
QQQ Invesco QQQ Trust, Series 1 0.68% 69%
VYM VANGUARD HIGH DIVIDEND YIELD INDEX FUND 0.66% 46%
SCHB Schwab U.S. Broad Market ETF 0.24% 53%
SPY 0.24% 56%
VOO VANGUARD 500 INDEX FUND 0.24% 56%
SPYM State Street(R) SPDR(R) Portfolio S&P 500(R) ETF 0.24% 56%
IVV iShares Core S&P 500 ETF 0.24% 56%
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.22% 54%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.21% 54%
RSP Invesco S&P 500 Equal Weight ETF 0.21% 44%
Other funds
FundGILD in fundFund compliant by weight
PBE Invesco Biotechnology & Genome ETF 4.43% 68%
TOWFX Towpath Focus Fund 2.99% 49%
PINK Simplify Health Care ETF 2.87% 59%
TOLL Tema Durable Quality ETF 2.13% 64%
MFSG MFS Active Growth ETF 1.12% 64%
BISVX Brown Advisory Sustainable Value Fund 1.12% 50%
TILGX Nuveen Large Cap Growth Fund Also TILRX 0.98% 65%
DFVX Dimensional US Large Cap Vector ETF 0.87% 44%
DEW WisdomTree Global High Dividend Fund 0.86% 25%
COWG Pacer US Large Cap Cash Cows Growth Leaders ETF 0.82% 76%
17 more funds
FundGILD in fundFund compliant by weight
QUS State Street(R) SPDR(R) MSCI USA StrategicFactors(SM) ETF 0.66% 55%
DVY iShares Select Dividend ETF 0.63% 16%
ETB Eaton Vance Tax-Managed Buy-Write Income Fund 0.62% 55%
CMLEX American Mutual Fund 0.60% 45%
SCHV Schwab U.S. Large-Cap Value ETF 0.57% 48%
SFY SoFi Select 500 ETF 0.56% 61%
INFO Harbor PanAgora Dynamic Large Cap Core ETF 0.55% 53%
VONV VANGUARD RUSSELL 1000 VALUE INDEX FUND 0.48% 41%
IWD iShares Russell 1000 Value ETF 0.44% 41%
ASG Liberty All-Star Growth Fund 0.39% 68%
FSKAX Fidelity Total Market Index Fund 0.24% 51%
INGIX VOYA U.S. STOCK INDEX PORTFOLIO 0.24% 55%
TIQRX Nuveen Equity Index Fund 0.22% 51%
ESG FlexShares STOXX US ESG Select Index Fund 0.22% 59%
SSO ProShares Ultra S&P500 0.19% 37%
GAB Gabelli Equity Trust Inc 0.02% 42%
GAB-PG Gabelli Equity Trust Inc 0.02% 42%

Sorted by GILD’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names GILD once, so a bond is not counted as the shares; 4 more funds name GILD in a way we cannot separate from its bonds, and are not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding GILD
InvestorFirmPositionWeightAs of
Dodge & Cox Dodge & Cox $3,249M 1.7% 2026-09-30
Ken Griffin Citadel Advisors $507M 0.1% 2026-09-30
Israel Englander Millennium Management $429M 0.1% 2026-09-30
Peter Brown Renaissance Technologies $306M 0.4% 2026-09-30
David Shaw D. E. Shaw & Co. $288M 0.1% 2026-09-30
Paul Tudor Jones Tudor Investment Corp $91M 0.1% 2026-09-30
Steven Cohen Point72 Asset Management $70M 0.1% 2026-09-30
Joel Greenblatt Gotham Asset Management $66M 0.1% 2026-09-30
Ray Dalio Bridgewater Associates $48M 0.2% 2026-09-30
Ken Fisher Fisher Asset Management $46M 0.0% 2026-09-30
John Rogers Ariel Investments $30M 0.3% 2026-09-30
Jefferies Jefferies Financial Group $7M 0.1% 2026-09-30
Chuck Royce Royce & Associates $4M 0.0% 2026-09-30
Wahed Invest Wahed Invest LLC $4M 0.4% 2026-06-30
Jeff Auxier Auxier Asset Management $1M 0.2% 2026-09-30
Sallie Krawcheck Ellevest $1M 0.1% 2026-09-30
Lee Ainslie Maverick Capital $0M 0.0% 2026-09-30
Mairs & Power Mairs & Power $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

174.48159.91145.34130.78116.212025-11-202026-05-222026-11-19

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
164.08
S2
165.72
S1
167.35
PIVOT
168.99
R1
170.62
R2
172.26
R3
173.89

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
143.31 – 161.11
±5.85% from 152.21, made 2026-09-28 · resolves 2026-10-05
STRONG BUY
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

BUY
19 indicators
OscillatorsSTRONG SELL
0 buy · 4 neutral · 3 sell
Moving averagesSTRONG BUY
9 buy · 0 neutral · 3 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)54.60NEUTRAL
Stochastic %K (14)20.11NEUTRAL
CCI (20)1.27NEUTRAL
Williams %R (14)-79.89NEUTRAL
MACD (12,26,9)-0.73SELL
ROC (10)-0.62SELL
Momentum (10)-1.04SELL
EMA (10)168.03SELL
SMA (10)168.62SELL
EMA (20)165.74BUY
SMA (20)166.77SELL
EMA (30)163.04BUY
SMA (30)162.41BUY
EMA (50)158.34BUY
SMA (50)156.77BUY
EMA (100)150.43BUY
SMA (100)146.87BUY
EMA (200)142.79BUY
SMA (200)141.13BUY

About GILD

Healthcare · Drug Manufacturers - General

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

gilead.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-10-28

ORB
Type · SCALP
160.29
Entry
158.36
Stop
164.14
Target
LOSS
Outcome · exit 159.22 (-0.67%)

Stop 158.36 Now 166.53 Target 164.14

Verdict

🟢 STRONG BUY SETUP

Strong confluence across multiple layers — outperforming the market by 12.2%, RSI in healthy zone, Wall Street broadly bullish. High conviction entry. Use `!plan GILD [entry] [stop] [target]` to size the position properly.

Scores: 4 bullish / 1 bearish

Grade verdict

No real edge — avoid

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 63
⏰ 4H RANGING 47
🕐 1H BEARISH 98
⏱ 15-Min RANGING 130
⏲ 5-Min RANGING 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-0.6%
Rate of change (10d)
2.7×
Volume vs its 20-day average
3.52
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

CLUSTER SELL   0 buys · 15 sells

Recent: O'Day Daniel Patrick sold 600433 sh @ $129.66 (2026-08-03); O'Day Daniel Patrick sold 592133 sh @ $131.34 (2026-08-03); O'Day Daniel Patrick sold 592733 sh @ $130.80 (2026-08-03)

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.